Frazier fund reports 8.7% NewAmsterdam Pharma stake

NewAmsterdam Pharma Co N.V.

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V. (NAMS) is the subject of this Amendment No. 7 to a Schedule 13D, in which multiple Frazier Life Sciences-affiliated funds and entities update their beneficial ownership of the company’s Ordinary Shares, including shares issuable upon exercise of warrants.

Frazier Life Sciences X, L.P. reports beneficial ownership of 7,329,857 Ordinary Shares (including 500,333 shares issuable upon exercise of warrants), representing 6.1% of the class, based on 119,537,169 shares outstanding as of August 3, 2026 plus those warrant shares. Frazier Lifesciences Sponsor LLC reports 3,968,000 shares (3.3%), Frazier Life Sciences Public Fund, L.P. reports 10,424,224 shares (8.7%), Frazier Life Sciences XI, L.P. reports 1,319,923 shares (1.1%), and Frazier Life Sciences XII, L.P. reports 365,231 shares (0.3%). James N. Topper and Patrick J. Heron share voting and investment power over the FLS X and Sponsor positions. The amendment also states that, other than transactions listed in Exhibit 10.1, no reporting person has traded the Ordinary Shares in the past 60 days.

Key Figures

FLS X beneficial ownership: 7,329,857 Ordinary Shares Sponsor ownership: 3,968,000 Ordinary Shares Frazier Life Sciences Public Fund stake: 10,424,224 Ordinary Shares +5 more

8 metrics

FLS X beneficial ownership 7,329,857 Ordinary Shares Including 500,333 shares issuable upon exercise of warrants; represents 6.1% of class

Sponsor ownership 3,968,000 Ordinary Shares Frazier Lifesciences Sponsor LLC; 3,801,000 shares plus 167,000 shares issuable upon exercise of warrants; 3.3% of class

Frazier Life Sciences Public Fund stake 10,424,224 Ordinary Shares Directly held by Frazier Life Sciences Public Fund, L.P.; represents 8.7% of outstanding shares

FLS XI ownership 1,319,923 Ordinary Shares Held by Frazier Life Sciences XI, L.P.; represents 1.1% of outstanding shares

FLS XII ownership 365,231 Ordinary Shares Held by Frazier Life Sciences XII, L.P.; represents 0.3% of outstanding shares

Shares outstanding baseline 119,537,169 Ordinary Shares NewAmsterdam Pharma Co N.V. shares outstanding as of August 3, 2026, per Form 10-Q

Warrant-based shares in FLS X and Sponsor 500,333 Ordinary Shares Ordinary Shares issuable upon exercise of warrants held collectively by FLS X and the Sponsor

Date of event requiring filing September 18, 2026 Date triggering Amendment No. 7 to Schedule 13D

Key Terms

beneficial ownership, warrants, Schedule 13D, initial public offering, +2 more

6 terms

beneficial ownership financial

"no members of such committee are attributed beneficial ownership of the securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

warrants financial

"Ordinary Shares that are issuable upon the exercise of Warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Schedule 13D regulatory

"This Amendment No. 7 to a Schedule 13D amends the statement"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

initial public offering financial

"in connection with the initial public offering ("IPO") of FLAC"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

Business Combination financial

"in connection with the initial public offering ("IPO") of FLAC and the Business Combination"

A business combination happens when two or more companies join together to operate as one, like two friends merging their teams into a single group. This is important because it can change how companies grow, compete, and make money, often making them bigger and more powerful in the market.

Ordinary Shares financial

"Ordinary Shares, nominal value EUR0.12 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in NAMS does Frazier Life Sciences X, L.P. report in this Schedule 13D/A?

Frazier Life Sciences X, L.P. reports beneficial ownership of 7,329,857 Ordinary Shares, including 500,333 shares issuable upon exercise of warrants, representing 6.1% of NewAmsterdam Pharma Co N.V.’s Ordinary Shares as calculated in the filing.

How many NAMS shares does Frazier Life Sciences Public Fund, L.P. hold?

Frazier Life Sciences Public Fund, L.P. directly holds 10,424,224 Ordinary Shares of NewAmsterdam Pharma Co N.V., which represents 8.7% of the outstanding Ordinary Shares based on 119,537,169 shares outstanding as of August 3, 2026.

What is the reported share count outstanding for NAMS used in this 13D/A?

The ownership percentages are calculated using 119,537,169 Ordinary Shares outstanding as of August 3, 2026, as reported by NewAmsterdam Pharma Co N.V. in its Quarterly Report on Form 10-Q filed on August 5, 2026.

Do the reporting persons disclose recent trading activity in NAMS shares?

The reporting persons state that, except as set forth in Exhibit 10.1, none of them has effected any transactions relating to NewAmsterdam Pharma Co N.V. Ordinary Shares during the past 60 days.

How are warrants reflected in Frazier Life Sciences’ NAMS ownership?

Frazier Life Sciences X, L.P. holds 333,333 warrants and Frazier Lifesciences Sponsor LLC holds 167,000 warrants, each warrant exercisable for one Ordinary Share. These 500,333 issuable shares are included in certain beneficial ownership and percentage calculations.

What role do James N. Topper and Patrick J. Heron play in the NAMS holdings?

James N. Topper and Patrick J. Heron are members of FHMLS X, L.L.C. and share voting and investment power over the FLS X Shares and the Sponsor Shares. Each is reported as beneficially owning 7,329,857 shares (6.1%), including shares underlying warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:59 PM Accepted by SEC EDGAR 09/22/2026 - 04:58 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

NEWAMSTERDAM PHARMA COMPANY N.V.

(Name of Issuer)

Ordinary Shares, nominal value EUR0.12 per share

(Title of Class of Securities)

N62509109

(CUSIP Number)

Jennifer Martin
1700 Seventh Ave, Suite 1120,
Seattle, WA, 98101
(206) 451-8040

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/18/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

Frazier Life Sciences X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,329,857.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,329,857.00

11

Aggregate amount beneficially owned by each reporting person

7,329,857.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 consists of (i) 6,829,524 Ordinary Shares and (ii) 500,333 Ordinary Shares that are issuable upon the exercise of warrants, each to acquire one Ordinary Share ("Warrants"). The percentage listed in row 13 is calculated based on (i) 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as increased by (ii) 500,333 Ordinary Shares issuable upon the exercise of Warrants.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

Frazier Lifesciences Sponsor LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,968,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,968,000.00

11

Aggregate amount beneficially owned by each reporting person

3,968,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.3 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 consists of (i) 3,801,000 Ordinary Shares and (ii) 167,000 Ordinary Shares that are issuable upon the exercise of Warrants. The percentage listed in row 13 is calculated based on (i) 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as increased by (ii) 500,333 Ordinary Shares issuable upon the exercise of Warrants.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

FHMLS X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,329,857.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,329,857.00

11

Aggregate amount beneficially owned by each reporting person

7,329,857.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 consists of (i) 6,829,524 Ordinary Shares and (ii) 500,333 Ordinary Shares that are issuable upon the exercise of Warrants. The percentage listed in row 13 is calculated based on (i) 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as increased by (ii) 500,333 Ordinary Shares issuable upon the exercise of Warrants.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

FHMLS X, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,329,857.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,329,857.00

11

Aggregate amount beneficially owned by each reporting person

7,329,857.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 consists of (i) 6,829,524 Ordinary Shares and (ii) 500,333 Ordinary Shares that are issuable upon the exercise of Warrants. The percentage listed in row 13 is calculated based on (i) 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as increased by (ii) 500,333 Ordinary Shares issuable upon the exercise of Warrants.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

Frazier Life Sciences Public Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 10,424,224.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 10,424,224.00

11

Aggregate amount beneficially owned by each reporting person

10,424,224.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.7 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

FHMLSP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 10,424,224.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 10,424,224.00

11

Aggregate amount beneficially owned by each reporting person

10,424,224.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.7 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

FHMLSP, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 10,424,224.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 10,424,224.00

11

Aggregate amount beneficially owned by each reporting person

10,424,224.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.7 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

Frazier Life Sciences XI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,319,923.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,319,923.00

11

Aggregate amount beneficially owned by each reporting person

1,319,923.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

FHMLS XI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,319,923.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,319,923.00

11

Aggregate amount beneficially owned by each reporting person

1,319,923.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

FHMLS XI, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,319,923.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,319,923.00

11

Aggregate amount beneficially owned by each reporting person

1,319,923.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.1 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

Frazier Life Sciences XII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 365,231.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 365,231.00

11

Aggregate amount beneficially owned by each reporting person

365,231.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

FHMLS XII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 365,231.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 365,231.00

11

Aggregate amount beneficially owned by each reporting person

365,231.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

FHMLS XII, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 365,231.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 365,231.00

11

Aggregate amount beneficially owned by each reporting person

365,231.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

James N. Topper

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,329,857.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,329,857.00

11

Aggregate amount beneficially owned by each reporting person

7,329,857.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 consists of (i) 3,801,000 Ordinary Shares held directly by Frazier Lifesciences Sponsor LLC, (ii) 167,700 Ordinary Shares that are issuable upon the exercise of Warrants held directly by Frazier Lifesciences Sponsor LLC, (iii) 3,028,524 Ordinary Shares held directly by Frazier Life Sciences X, L.P. and (iv) 333,333 Ordinary Shares that are issuable upon the exercise of Warrants held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on (i) 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as increased by (ii) 500,333 Ordinary Shares issuable upon the exercise of Warrants held collectively by Frazier Lifesciences Sponsor LLC and Frazier Life Sciences X, L.P.

SCHEDULE 13D

CUSIP Number(s): N62509109

1

Name of reporting person

Patrick J. Heron

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,329,857.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,329,857.00

11

Aggregate amount beneficially owned by each reporting person

7,329,857.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 consists of (i) 3,801,000 Ordinary Shares held directly by Frazier Lifesciences Sponsor LLC, (ii) 167,700 Ordinary Shares that are issuable upon the exercise of Warrants held directly by Frazier Lifesciences Sponsor LLC, (iii) 3,028,524 Ordinary Shares held directly by Frazier Life Sciences X, L.P. and (iv) 333,333 Ordinary Shares that are issuable upon the exercise of Warrants held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on (i) 119,537,169 Ordinary Shares that were outstanding as of August 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as increased by (ii) 500,333 Ordinary Shares issuable upon the exercise of Warrants held collectively by Frazier Lifesciences Sponsor LLC and Frazier Life Sciences X, L.P.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, nominal value EUR0.12 per share
(b)	Name of Issuer: NEWAMSTERDAM PHARMA COMPANY N.V.
(c)	Address of Issuer's Principal Executive Offices: Gooimeer 2-35, 1411 , Naarden, NETHERLANDS , 1411 DC.
Item 1 Comment: This Amendment No. 7 ("Amendment No. 6") to Schedule 13D amends the statement on Schedule 13D filed on December 2, 2022 (the "Original Schedule 13D") as amended on June 7, 2023, August 15, 2023, February 21, 2024, December 17, 2024, August 20, 2025 and November 4, 2025 (the "Prior Amendments", and together with the Original Schedule 13D and this Amendment No. 7, the "Schedule 13D"). Except as otherwise specified in this Amendment No. 7, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 7 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.
Item 2.	Identity and Background
(a)	The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences X, L.P. ("FLS X") Frazier Lifesciences Sponsor LLC ("Sponsor") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron" and together with Topper, the "Members")
(b)	The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304
(c)	Item 2(c) is hereby amended and restated in its entirety to read as follows: The Sponsor's principal business is to act as the sponsor of Frazier Lifesciences Acquisition Corporation, the Issuer's predecessor ("FLAC"), in connection with the initial public offering ("IPO") of FLAC and the Business Combination (as defined below). FLS X, FLS XI, FLSPF and FLS XII are venture capital funds concentrating in life sciences and related fields. The sole business of FHMLS X, L.P. is to serve as general partner of FLS X. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS X, L.P. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. The sole business of FHMLS XII, L.P. is to serve as general partner of FLS XII. The sole business of FHMLS XII, L.L.C. is to serve as general partner FHMLS XII, L.P. The principal business of the Members is to manage FLS X, FLSPF, FLS XI, FLS XII, FHMLS X, L.P., FHMLS X, L.L.C., FHMLSP, L.P., FHMLSP, L.L.C., FHMLS XI, L.P., FHMLS XI, L.L.C., FHMLS XII, L.P., FHMLS XII, L.L.C., and a number of affiliated partnerships with similar businesses. FLS X is also the sole member of the Sponsor and Mr. Topper serves as a manager of the Sponsor.
(f)	The information contained in row 6 of each Reporting Person's cover page to this Schedule 13D is incorporated by reference.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLS X directly holds 3,028,524 Ordinary Shares and 333,333 warrants ("Warrants") to acquire an equivalent number of Ordinary Shares (collectively, the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. Sponsor directly holds 3,801,000 Ordinary Shares and 167,000 Warrants (the "Sponsor Shares"). FLS X is the sole member of Sponsor. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the Sponsor Shares. FLSPF directly holds 10,424,224 Ordinary Shares (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS XI directly holds 1,319,923 Ordinary Shares (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 365,231 Ordinary Shares (the "FLS XII Shares"). FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g).
(c)	Except as set forth on Exhibit 10.1 of this Schedule 13D, none of the Reporting Persons has effected any transactions relating to the Ordinary Shares during the past 60 days.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 10.1 Transactions Relating to the Ordinary Shares of the Issuer During the Past Sixty (60) Days Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13D/A filed on November 5, 2025)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences X, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:	09/22/2026

Frazier Lifesciences Sponsor LLC

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P., Sole Member of Frazier Lifesciences Sponsor LLC
Date:	09/22/2026

FHMLS X, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:	09/22/2026

FHMLS X, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:	09/22/2026

Frazier Life Sciences Public Fund, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:	09/22/2026

FHMLSP, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:	09/22/2026

FHMLSP, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:	09/22/2026

Frazier Life Sciences XI, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:	09/22/2026

FHMLS XI, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:	09/22/2026

FHMLS XI, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:	09/22/2026

Frazier Life Sciences XII, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:	09/22/2026

FHMLS XII, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:	09/22/2026

FHMLS XII, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:	09/22/2026

James N. Topper

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney
Date:	09/22/2026

Patrick J. Heron

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney
Date:	09/22/2026